Susquehanna Fundamental Investments LLC Acquires Shares of 94,624 Myriad Genetics, Inc. (NASDAQ:MYGN)

Susquehanna Fundamental Investments LLC acquired a new position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 94,624 shares of the company's stock, valued at approximately $2,315,000. Susquehanna Fundamental Investments LLC owned approximately 0.10% of Myriad Genetics at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Hexagon Capital Partners LLC boosted its position in shares of Myriad Genetics by 75.3% during the second quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company's stock valued at $28,000 after buying an additional 491 shares during the last quarter. Innealta Capital LLC purchased a new position in Myriad Genetics in the second quarter worth about $36,000. Point72 DIFC Ltd purchased a new position in Myriad Genetics in the second quarter worth about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Myriad Genetics during the 2nd quarter valued at about $82,000. Finally, Neo Ivy Capital Management bought a new stake in Myriad Genetics during the 2nd quarter valued at approximately $85,000. Institutional investors own 99.02% of the company's stock.

Insider Transactions at Myriad Genetics

In other news, Director Colleen F. Reitan sold 46,012 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the sale, the director now owns 42,533 shares of the company's stock, valued at $1,188,797.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Heinrich Dreismann sold 10,000 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $27.05, for a total value of $270,500.00. Following the completion of the transaction, the director now directly owns 121,648 shares in the company, valued at $3,290,578.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Colleen F. Reitan sold 46,012 shares of the company's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the transaction, the director now owns 42,533 shares of the company's stock, valued at $1,188,797.35. The disclosure for this sale can be found here. Company insiders own 2.10% of the company's stock.

Myriad Genetics Price Performance

Shares of NASDAQ MYGN traded down $0.23 on Tuesday, hitting $27.16. The company's stock had a trading volume of 305,951 shares, compared to its average volume of 719,536. Myriad Genetics, Inc. has a 12-month low of $13.82 and a 12-month high of $29.30. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -9.55 and a beta of 1.92. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.78. The stock has a 50 day moving average of $27.46 and a 200-day moving average of $24.32.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. The business had revenue of $211.50 million for the quarter, compared to the consensus estimate of $206.44 million. Myriad Genetics had a negative net margin of 19.35% and a negative return on equity of 5.64%. The company's quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. As a group, research analysts predict that Myriad Genetics, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

MYGN has been the topic of a number of research reports. Piper Sandler lifted their price objective on Myriad Genetics from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 13th. Scotiabank boosted their price objective on Myriad Genetics from $29.00 to $34.00 and gave the company a "sector outperform" rating in a report on Tuesday, August 13th. Wells Fargo & Company assumed coverage on Myriad Genetics in a report on Tuesday, August 27th. They issued an "overweight" rating and a $35.00 target price for the company. JPMorgan Chase & Co. boosted their price target on Myriad Genetics from $17.00 to $20.00 and gave the stock an "underweight" rating in a research report on Wednesday, August 7th. Finally, Jefferies Financial Group reaffirmed an "underperform" rating and set a $20.00 target price (down from $25.00) on shares of Myriad Genetics in a research report on Monday, June 3rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $28.91.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.